|
More drugs added to benefit scheme list THE Australian Government has extended the listing of several drugs on the Pharmaceutical Benefits Scheme (PBS) for the treatment of breast cancer, diabetes and hepatitis B.Also, for the first time, high-risk patients have access to cholesterol-lowering drugs, regardless of their cholesterol levels. These changes will benefit to more than 366,000 patients at a cost of up to $860 million over four years. Herceptin (trastuzumab) will be available to treat patients with HER2 positive early stage breast cancer, following surgery. Breast cancer affects 14,000 Australians each year. Of these, around 2,000 people have HER2 positive breast cancer. The listing of Herceptin should significantly improve health outcomes for patients and will cost $470 million between 2006-07 and 2009-10. The listing of the cancer drugs docetaxel (Taxotere) and paclitaxel (Taxol , Anzatax, Paclitaxel Ebewe) will also be extended for the treatment of early breast cancer at a cost to the Government of $35.7 million over four years. About 3,000 patients over four years will benefit from this change. Cardiovascular disease is Australia's greatest health problem affecting about 3.5 million people each year. The new eligibility criteria for cholesterol-lowering drugs will benefit an additional 250,000 patients at a cost of around $150 million over the next four years. Diabetes has a substantial impact on the health of Australians. Lantus(r) (insulin glargine) and Levemir(r) (insulin detemir) will be available on the PBS, benefiting an expected 110,000 people in the first year of listing. This will cost up to $150 million over four years. Hepatitis B sufferers will benefit from the anti-viral drug peginterferon alfa-2a (Pegasys(r)). The drug is already on the PBS for the treatment of hepatitis C and has been extended on the PBS for the treatment of hepatitis B. This will cost the Government $55.2 million over four years, and benefit around 1,000 patients each year. |
About Us | Our Publications | Shopping | Visa Enquiries | Information Days | Links | Advertising | Privacy Policy
© 2005 Consyl Publishing & Publicity Ltd.